– UK, London – IXICO plc (LON: IXI), the data analytics company delivering insights in neuroscience, today announced the appointment of Kate Rogers to its Board as a Non-Executive Director with effect from 21 January 2022.
“We are delighted to welcome Kate to IXICO and look forward to benefitting from her broad and deep experience of both the pharmaceutical sector and international finance,” said Board Chair, Charles Spicer.
Kate will also join the Audit Committee as Chair.
About Kate Rogers
Kate is currently leading the transformation of Glaxo SmithKline’s global finance organization having previously worked as CFO for Laboratoire Glaxo SmithKline SaS as well as other senior finance roles within GSK. Kate holds a Bachelor of Science degree in Engineering from Oxford University and qualified as a Chartered Management Accountant in 1999.
IXICO is dedicated to delivering insights into neuroscience. Our mission is to transform the progression of our biopharmaceutical clients’ neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.
IXICO’s data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection, and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better-informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
For more information: https://ixico.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.